Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
Scientists may have finally found a way to deal with one of developing world's worst problems in healthcare — faulty and inadequate cold chain for vaccine storage. British scientists from Oxford University have found a way to keep vaccines stable even in room temperature.
In this arena, we believe there should be two broad priorities for India. First, to ensure that there is timely access to affordable quality medicine for the underprivileged. Second, due to the global scale and impact of the Indian pharmaceutical industry, to ensure that we give it the most comprehensive support that it deserves.
Surging growth and global operations ensure they can’t be family-run any longer.
Avesthagen’s systems biology approach to novel products targets more than land based organisms – dives deep into new products from the OceanAvesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation. Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well. Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.
India might be shining for multinational drugmakers, but when it actually comes to introducing innovator drugs the $20 billion Indian pharma market is light years away.
Delhi High Court dismisses six petitions of drug majors.
In a first-ever initiative to bring down prices of expensive cancer medication, the government plans to retail them through its ‘Jan Aushadhi’ stores, which offer essential ‘unbranded’ drugs at discounted rates. It has already initiated talks with domestic pharma companies to procure cancer drugs.
The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc.
A global study by Health Action International, a non-government body, on the price variations of Ciproflaxin, a commonly used medicine in 93 countries, found the price charged by Bayer, the originator of the drug, to be the lowest in India.
Troikaa Pharmaceuticals, a Gujarat based fast growing healthcare company, is likely to get US patent for its novel drug delivery form of Diclofenac injections-Dyanapar AQ.
Union Health and Family Welfare Minister Ghulam Nabi Azad and Gujarat Chief Minister Narendra Modi, on Saturday invited expatriates to invest in the country.
In one stroke, Swiss pharma giant Novartis AG could break into the league of top five players in the Rs 600-crore plus Indian eyecare market from its current position at 13, if its takeover of Alcon goes through seamlessly and eventually results in integration of Alcon India into the Indian arm of Novartis. Such a combined entity of Novartis and Alcon would then command a marketshare of 7.5% in the domestic eyecare market, just 1.4% less compared with the third and fourth ranked companies, FDC and Sun Pharma, which command 8.9% marketshare each.
Domestic drug companies, who have been challenging drug patents in the US and Europe, are now taking the first steps to challenge patents granted in India to companies based there.
The domestic pharmaceutical industry has urged the government to withdraw a study launched by the World Health Organization (WHO) in consultation with the Union ministry of health on implementing 'Data Exclusivity' in India.
Pharmaceutical major Piramal Healthcare is planning to raise Rs 1,000 crore (Rs 10 billion) in the next 6-8 months, a senior company official said here on Thursday.
The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out describing the deal.
Pharma major Ranbaxy Laboratories today said it has launched a new dermatological product Lulifin in the Indian market. This follows a strategic in-licensing agreement with Summit Pharmaceuticals International Corporation, Japan, Ranbaxy said.
The year had just begun, when Pfizer announced its $68-billion deal to acquire Wyeth, in January. On its heels came Merck & Co's $ 41-billion deal to acquire Schering-Plough Corporation, in March.